Skip to main content
  • NIH begins study of allergic reactions to Moderna, Pfizer-BioNTech COVID-19 vaccines

    A clinical trial is underway to determine whether people who are highly allergic or have a mast cell disorder are at increased risk for an immediate, systemic allergic reaction to the Moderna or Pfizer-BioNTech COVID-19 vaccines. A systemic allergic reaction to a vaccine occurs in one or more parts of the body beyond the injection site.

  • AstraZeneca Covid-19 vaccine show 79% efficacy against symptomatic and 100% efficacy against severe disease

    The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalisation. This interim safety and efficacy analysis was based on 32,449 participants accruing 141 symptomatic cases of COVID-19. The trial had a 2:1 randomisation of vaccine to placebo. Vaccine efficacy was consistent across ethnicity and age. Notably, in participants aged 65 years and over, vaccine efficacy was 80%.

  • Indian scientists develop artificial enzyme to keep HIV virus in check

    People suffering from Human Immunodeficiency Virus (HIV) infection can now hope to have a better quality of life with researchers at the Bengaluru-based Indian Institute of Science (IISc) developing a nano alternative to a natural enzyme that is used to block reactivation and replication of the virus in the host’s immune cells.

  • Certain high blood pressure medications may alter heart risk in people with HIV

    When people with human immunodeficiency virus (HIV) develop high blood pressure, the type of medication chosen for their initial treatment may influence their risk of heart disease, stroke and heart failure, according to new research published today in Hypertension, an American Heart Association journal.

  • Zydus seeks DCGI approval for the use of Pegylated Interferon alpha-2b in COVID-19

    Zydus Cadila announced that its Phase III clinical trials with Pegylated Interferon Alpha 2b, PegiHepTM has shown promising results in treating COVID-19. In what could be a breakthrough in the disease management of COVID-19, the interim results indicate that PegIFN when administered early on, could help patients recover faster and avoiding much of the complications seen in the advanced stages of the disease. PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents.

    admin Mon, 04/05/2021 - 15:29
  • Genome Sequencing Shows New Coronavirus Variants Drive Pandemic Surges


    Genome sequencing of thousands of SARS-CoV-2 samples shows that surges of COVID-19 cases are driven by the appearance of new coronavirus variants, according to new research from the School of Veterinary Medicine at the University of California, Davis, published April 1 in Scientific Reports.

  • UConn Researcher Develops Successful Zika Virus Vaccine in Preclinical Studies

    UConn researcher Paulo Verardi, associate professor of pathobiology and veterinary science in the College of Agriculture, Health and Natural Resources, has demonstrated the success of a vaccine against Zika virus and recently published his findings in Scientific Reports, a Nature Research publication.

  • New hope for mitochondrial disorders

    Efforts to find a treatment for mitochondrial disorders is set to get a major boost with a team of researchers at the Department of Biotechnology’s National Institute of Immunology (DBT-NII) figuring out a way to tackle autosomal dominant progressive external ophthalmoplegia (adPEO), which is a widely prevalent mitochondrial disorder.

  • Salt substitution is effective to reduce blood pressure in rural India

    Replacing regular common salt consumed by hypertensive patients in rural areas with a salt substitute can have a significant impact in terms of lowering their blood pressure, a new study by The George Institute for Global Health (GIGH) has revealed.

  • Cold-virus saved lives from corona virus in India, says Research

    Despite rising cases of corona infection, the rate of deaths due to Covid-19 outbreaks has been lower in India than in the US and the United Kingdom. This has emerged in a new study by scientists of the National Institute of Immunology (NII) and All India Institute of Medical Sciences (AIIMS) based in New Delhi. Researchers say one of the reasons for the decrease in the rate of deaths caused by Covid-19 in India may be prior exposure to the corona responsible for the common cold.

Subscribe to Research News

Search this website